Navigation Links
Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests
Date:12/11/2008

ong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The company's first test, miRview(TM) squamous, is now commercially available through its Philadelphia-based CLIA-certified lab.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease and the timing of introduction of additional microRNA-based diagnostic tests, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic tools, which is unproven and may never lead to marketable products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its candidate tools, products and services, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
2. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
3. Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
4. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
5. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
6. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
7. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
8. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
9. Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
10. MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
11. Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics miRview(TM) Squamous Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Yesterday, former Congressman ... medical device manufacturing facility. Rep. Kennedy and ... monitors facilitate cutting-edge research in neurological disease and ... mental health advocate, Garen Staglin , created ... fostering fundamental changes that will radically accelerate the ...
(Date:7/10/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the sale to Galderma of all rights to Restylane, ... Valeant for $1.4 billion in cash, pursuant to the ... its acquisition of Galderma. "We are ... a company that is firmly committed to the aesthetic ...
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Feb. 9, 2011 Reportlinker.com announces that a ... catalogue: European Market for Dental ... http://www.reportlinker.com/p0377961/European-Market-for-Dental-Prosthetics-and-CAD/CAM-Devices-2011.html In 2010, ... crowns, bridges and dentures, were valued at over ...
... 2011 Protect Pharmaceutical Corporation (OTC Bulletin Board: ... of two patents and patents-applications to Grunenthal GmbH, a German ... discovery and research. The patent portfolio includes innovative pain drugs ... Ram Sesha, Protect,s Chief Operating Officer, said, "We are ...
Cached Medicine Technology:Reportlinker Adds European Market for Dental Prosthetics and CAD/CAM Devices 2011 2Protect Pharma Sells Patent Portfolio to Grunenthal GmbH 2
(Date:7/10/2014)... New York (PRWEB) July 10, 2014 ... dedicated to protecting the rights of victims injured ... has brought a lawsuit over allegations that the ... body by a power morcellator used during a ... been filed against Richard Wolf Medical Instruments Corporation ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Most professional football ... return to the game, a new study finds. ... but their rate of return after surgery to fix ... The new study included 60 players who had ... this procedure successfully returned to play, defined as playing ...
(Date:7/10/2014)... Thompson HealthDay Reporter THURSDAY, ... wars that break out regularly between outspoken celebrities or loudmouth ... own relationship, a new study suggests. High amounts of ... if the couple is in a long-term relationship, according to ... In turn, that friction can lead to cheating and breakups, ...
(Date:7/10/2014)... device developed at the Massachusetts General Hospital (MGH) Center ... can be cultured to establish cell lines for genetic ... issue of Science , an MGH research team ... genetic mutation over time and changing susceptibility to therapeutic ... the blood that represent those present in metastatic deposits, ...
(Date:7/10/2014)... to bump up their grade point averages during college, ... a library or study hall, but in a gym. ... who were members of the recreational sports and fitness ... years had higher GPAs than those who weren,t. ... stayed in school longer. An increase of 3.5 percent ...
Breaking Medicine News(10 mins):Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Shoulder Surgery Gets NFL Players Back in the Game 2Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 3Health News:Want a higher GPA in college? Join a gym 2
... trial results performed by the Radiation Therapy Oncology ... absence (co-deletion) of chromosomes 1p and 19qhave definitive ... of adult patients with pure and mixed anaplastic ... associated with a substantially better prognosis and near-doubling ...
... 30 per cent of patients hospitalized after a stroke develop ... Researchers found patients who experience delirium after stroke are ... to be discharged to a long-term care facility, nursing home ... recognition and prevention of delirium are important for a quick ...
... HealthDay Reporter , THURSDAY, Jan. 19 (HealthDay News) -- ... child between 2004 and 2008 did not use birth control, and ... a new government study finds. Although the number of teens ... years, the U.S. teen birth rate is still the highest of ...
... now well established, a growing body of research also suggests ... developmental disorder affecting nearly one in 100 children. Using a ... weight is an important environmental factor contributing to the risk ... discordant twins -- twin pairs in which only one twin ...
... THURSDAY, Jan. 19 (HealthDay News) -- Amid hints that statins ... preventing or treating certain types of cancer, new research sheds ... cancer in its tracks among certain women. The ... cells, but some women with breast cancer have mutant forms ...
... gene known as the guardian of the genome is ... aggressive types of cancer, scientists at the European Molecular ... and the University Hospital, all in Heidelberg, Germany, have ... , also presents the first whole genome sequence of ...
Cached Medicine News:Health News:Abnormal chromosome indicator of treatment and outcome in patients with rare brain tumor 2Health News:Abnormal chromosome indicator of treatment and outcome in patients with rare brain tumor 3Health News:Study finds delirium after stroke linked to poorer outcomes for patients 2Health News:More Than Half of Teens Who Gave Birth Weren't Using Contraception: CDC 2Health News:More Than Half of Teens Who Gave Birth Weren't Using Contraception: CDC 3Health News:Another clue in the mystery of autism 2Health News:Study Hints That Statins Might Fight Breast Cancer 2Health News:Rigged to explode? 2Health News:Rigged to explode? 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: